The assay will use Genomic Vision technology and be used to study the role of telomere length in complex diseases.
As the firm continues to move toward commercialization of its test, its loss dropped to $3.8 million, or $.12 per share, from $4.7 million, $.16 per share, in the same period last year.
Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
The financing round was led by Triventures, and included Inimiti Capital and Glilot Capital Partners.
Malaysia-based ScienceVision has agreed to commercialize and distribute the PierianDx Clinical Genomics Workspace platform in Southeast Asian countries.
BioClin is developing a monoclonal antibody-based treatment for relapsed/refractory metastatic urothelial carcinoma with FGFR3 molecular alterations.
George Church's Nebula is teaming with Hong Kong startup Longenesis to create a secure platform for individuals and biobanks to sell access to their genomes.
Illumina said the acquisition will help enable a standardized process for sequencing and analysis and speed up the time it take to get a result.
The increase was drive by revenue growth in Cancer Genetics' discovery services unit, which included the impact of recently acquired CRO VivoPharm.
Unicancer will provide patients with centralized laboratory testing performed by Agendia, and also adopt the company's NGS kits for decentralized testing.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.
The company said the disposal of these two businesses is part of a strategy to focus entirely on the molecular diagnostics market.
PavMed subsidiary Lucid Diagnostics secured exclusive global rights to develop and commercialize genetic biomarker-based diagnostic tests using EsoCheck technology.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
The company is expecting that existing users from its technology access program are likely to purchase instruments when they become available later this year.
The company anticipates 2018 revenues in the range of €11 million to €12 million, excluding the impact of recently acquired TGR Biosciences.
The revenue increase was primarily driven by collaborative development services activities with partners including Qiagen.
The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.
BC Platforms will incorporate Sentieon's next-generation sequencing data-processing software into its integrated genomics and clinical data products.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.
Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.
In Science this week: gut microbiome influences liver cancer growth, spread; and more.